<DOC>
	<DOCNO>NCT01693159</DOCNO>
	<brief_summary>The SUPPORT trial open-label , prospective , randomize , national multicenter intervention study evaluate effectiveness ethyl-2-cyanoacrylate versus standard treatment institution pain intensity QoL patient locally advanced head neck cancer suffer painful cetuximab-induced rhagades radioimmunotherapy .</brief_summary>
	<brief_title>Effects ECA Quality Life Head Neck Cancer Patients Suffering From Cetuximab-induced Rhagades</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Ethyl 2-cyanoacrylate</mesh_term>
	<criteria>Locally advanced squamous cell carcinoma head neck participation HICAREphaseIVtrial Cetuximabinduced painful rhagades , i.e . SUPO Score 23 ( see Figure 2 ) Compliance photo documentation Ability subject understand character individual consequence clinical trial Written inform consent Cetuximabinduced rhagades without pain , i.e . SUPO Score 1 Cetuximabinduced rhagades , SUPO Score 4 , i.e . superinfection rhagades Patients enrol HICARE trial Substance misuse , psychoactive substance abuse psychological/social condition lead decreased patient ' compliance possible bad influence result study Known allergic reaction ethyl2cyanoacrylate ( ECA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Painful cetuximab-induced rhagades</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Head neck cancer</keyword>
</DOC>